drugset / Trial / NCT03536208

Biological Effect of Warfarin on Pancreatic Cancer

NCT03536208

NaSingle-groupOpen-labelTreatment

Summary

This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma.

Timeline

Start
2019-05-15
Primary completion
2021-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Warfarin Small molecule 1 mg Oral
Subject Warfarin Small molecule 2 mg Oral
Subject Warfarin Small molecule 2.5 mg Oral
Subject Warfarin Small molecule 4 mg Oral
Subject Warfarin Small molecule 5 mg Oral